indirubin has been researched along with 6-bromoindirubin-3'-oxime in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Greengard, P; Leost, M; Magiatis, P; Meijer, L; Mikros, E; Musacchio, A; Myrianthopoulos, V; Pearl, L; Polychronopoulos, P; Roe, SM; Skaltsounis, AL; Tarricone, A | 1 |
| Bettayeb, K; Ferandin, Y; Kritsanida, M; Lozach, O; Magiatis, P; Meijer, L; Polychronopoulos, P; Skaltsounis, AL | 1 |
| Grundt, P; Jones-Brando, L; Krivogorsky, B; Yolken, R | 1 |
| Choi, SJ; Kim, YC; Lee, SH; Lee, SK; Park, EJ; Park, SW | 1 |
| Hanada, S; Kanda, Y; Miyairi, S; Saito, H; Suzuki, T; Tabata, K | 1 |
| Alam, MS; Hamid, H; Khan, I; Tantray, MA | 1 |
| Gaboriaud-Kolar, N; Gerolymatos, P; Horne, DA; Jove, R; Mikros, E; Myrianthopoulos, V; Nam, S; Skaltsounis, AL; Vougogiannopoulou, K | 1 |
| Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
| Haraguchi, T; Ichimaru, Y; Ishige, K; Ito, Y; Kobayashi, S; Kosuge, Y; Miyagishi, H; Miyairi, S; Ohashi, S; Saito, H | 1 |
| Bai, G; Chen, Y; Wang, H; Wang, J; Wang, Z; Wei, C; Xu, Y; Yao, Q; Zhang, L | 1 |
| Bai, BM; Kumar, A; Nisha, CM; Pal, D; Vimal, A | 1 |
| Czapka, A; Fischer, D; Grune, C; König, S; Pergola, C; Skaltsounis, AL; Vougogiannopoulou, K; Werz, O | 1 |
2 review(s) available for indirubin and 6-bromoindirubin-3'-oxime
| Article | Year |
|---|---|
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Topics: Alzheimer Disease; Animals; Bipolar Disorder; Clinical Trials as Topic; Diabetes Mellitus; Drug Discovery; Glycogen Synthase Kinase 3; Humans; Models, Molecular; Neoplasms; Patents as Topic; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2017 |
Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.
Topics: Antineoplastic Agents; Cell Survival; Chemistry, Pharmaceutical; Drugs, Chinese Herbal; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oximes; Structure-Activity Relationship | 2021 |
10 other study(ies) available for indirubin and 6-bromoindirubin-3'-oxime
| Article | Year |
|---|---|
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Topics: Cyclin-Dependent Kinases; Glycogen Synthase Kinase 3; Indoles; Models, Molecular; Oximes; Structure-Activity Relationship | 2004 |
3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.
Topics: Antineoplastic Agents; Bromine; Cell Death; Cell Line, Tumor; Chlorine; Drug Screening Assays, Antitumor; Fluorine; Humans; Indoles; Iodine; Models, Molecular; Stereoisomerism; Structure-Activity Relationship | 2006 |
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.
Topics: Animals; Antiprotozoal Agents; Drugs, Chinese Herbal; Indoles; Isatis; Parasitic Sensitivity Tests; Quinazolines; Toxoplasma | 2008 |
Novel small molecule activators of beta-catenin-mediated signaling pathway: structure-activity relationships of indirubins.
Topics: beta Catenin; Cell Line; Dose-Response Relationship, Drug; Humans; Indoles; Signal Transduction; Structure-Activity Relationship | 2009 |
Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Molecular Structure; Neuroblastoma; Stereoisomerism; Structure-Activity Relationship | 2011 |
Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2016 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |
Indirubin derivatives protect against endoplasmic reticulum stress-induced cytotoxicity and down-regulate CHOP levels in HT22 cells.
Topics: Animals; Apoptosis; Cell Line; Down-Regulation; Endoplasmic Reticulum Stress; Indoles; Mice; Protective Agents; Structure-Activity Relationship; Transcription Factor CHOP; Tunicamycin | 2017 |
Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
Topics: Azepines; Binding Sites; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Indole Alkaloids; Indoles; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Oximes; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Structure, Secondary; Pyrroles; Static Electricity; Thermodynamics; Thiadiazoles | 2016 |
The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference.
Topics: Adolescent; Adult; Aged; Animals; Chickens; Cytokines; Dose-Response Relationship, Drug; Female; Glycogen Synthase Kinase 3; Humans; Indoles; Inflammation Mediators; Male; Middle Aged; Monocytes; Oximes; Prostaglandin Antagonists; Prostaglandins; Young Adult | 2020 |